Isabel Rodríguez-Goncer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Isabel Rodríguez-Goncer has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- José María Aguado
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
26 shared publications - Mario Fernández-Ruiz
Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain
25 shared publications - Francisco López-Medrano
Unit of Infectious Diseases, University Hospital ‘12 de Octubre’, Madrid, Spain
22 shared publications - Rafael San Juan
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
20 shared publications - Tamara Ruiz-Merlo
Unit of Infectious Diseases Hospital Universitario “12 de Octubre” Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12) Madrid Spain
12 shared publications - Amado Andrés
Nephrology Department Hospital Universitario 12 de Octubre Madrid Spain
11 shared publications
Latest Publications
- 12 August 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70301
Infectious Complications in Living Donation Versus Donation After Brain Death Kidney Transplantation
Background: Kidney transplantation from living donors (LDs) offers benefits over donation after brain death (DBD). Whether LD independently protects against infection incidence remains unclear. Methods: We compared posttransplant infection between LD ( n = 102) and DBD ( n = 401) groups in a prospective observational cohort of 503 KT recipients at a tertiary‐care center. Crude and adjusted associations between donor type and infection risk were assessed using propensity score (PS) modeling and multivariable Cox regression. Results: Cumulative incidence rates of overall and bacterial infection were 58.6% and 43.7%, respectively. Compared to DBD recipients, LD patients had lower crude risks for overall (hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.39–0.74; p ‐value < 0.001) and bacterial infection (HR: 0.59; 95% CI: 0.41–0.87; p ‐value = 0.007). In PS‐based models, donor type was no longer significant for overall (PS‐adjusted HR: 0.78; 95% CI: 0.52–1.18; p ‐value = 0.244) or bacterial infection (PS‐adjusted HR: 0.94, 95% CI: 0.59–1.50; p ‐value = 0.802). Similar effect modification appeared for secondary outcomes and adjusted multivariable models. Conclusion: Donor type did not independently influence posttransplant infection risk after adjustment for baseline recipient factors. Lower infection incidence in LD recipients may reflect favorable recipient‐ and transplant‐related characteristics rather than donor‐specific factors. image
- 12 August 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70301
Infectious Complications in Living Donation Versus Donation After Brain Death Kidney Transplantation
Background: Kidney transplantation from living donors (LDs) offers benefits over donation after brain death (DBD). Whether LD independently protects against infection incidence remains unclear. Methods: We compared posttransplant infection between LD ( n = 102) and DBD ( n = 401) groups in a prospective observational cohort of 503 KT recipients at a tertiary‐care center. Crude and adjusted associations between donor type and infection risk were assessed using propensity score (PS) modeling and multivariable Cox regression. Results: Cumulative incidence rates of overall and bacterial infection were 58.6% and 43.7%, respectively. Compared to DBD recipients, LD patients had lower crude risks for overall (hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.39–0.74; p ‐value < 0.001) and bacterial infection (HR: 0.59; 95% CI: 0.41–0.87; p ‐value = 0.007). In PS‐based models, donor type was no longer significant for overall (PS‐adjusted HR: 0.78; 95% CI: 0.52–1.18; p ‐value = 0.244) or bacterial infection (PS‐adjusted HR: 0.94, 95% CI: 0.59–1.50; p ‐value = 0.802). Similar effect modification appeared for secondary outcomes and adjusted multivariable models. Conclusion: Donor type did not independently influence posttransplant infection risk after adjustment for baseline recipient factors. Lower infection incidence in LD recipients may reflect favorable recipient‐ and transplant‐related characteristics rather than donor‐specific factors. image
- Open Access
- 1 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies
Background: Bispecific antibodies (BsAbs) have revolutionized multiple myeloma (MM) treatment but are associated with infectious complications. This study aims to characterize the incidence, microbiological patterns, and risk factors for infection in this population. Methods: We conducted an observational cohort study of adult MM patients treated with BsAbs at a single center between 2020 and 2025. Clinical and microbiological features of different types of infection were analyzed. Risk factors for recurrent events were assessed by Cox regression. Results: Among 92 patients receiving 98 BsAb courses, 352 infectious episodes were identified (incidence rate: 3.20 episodes per BsAbs course-year). Most common syndromes were respiratory (71.3%) and digestive (11.9%), with predominant viral etiology (62.8%). Severe (grade ≥3) infections occurred in 45.9% of courses. Anti-BCMA BsAbs carried a higher infection risk than anti-GPRC5D therapy (aHR: 1.41, 95% CI: 1.02–1.94; P-value = 0.035). Previous BsAb exposure (aHR: 1.75, 95% CI: 1.23–2.50; P-value = 0.002), allogeneic hematopoietic stem-cell transplantation (aHR: 1.59, 95% CI: 1.12–2.26; P-value = 0.010), and development of immune effector cell-associated neurotoxicity syndrome (ICANS) (aHR: 3.23, 95% CI: 1.27–8.19; P-value = 0.001) increased the risk of infection. Intravenous immunoglobulin (IVIg) therapy was protective (aHR: 0.68, 95% CI: 0.53–0.86; P-value = 0.002). Concurrent infections were documented in only 6.8% of first episodes of cytokine release syndrome (CRS). Conclusions: BsAb therapy for MM is associated with a high infection burden, predominantly respiratory and gastrointestinal. Risk is driven by cumulative immunosuppression and therapy for ICANS, while IVIg therapy reduces this susceptibility. Infections are uncommon during CRS episodes.
- 1 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Open AccessEpidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies
Background: Bispecific antibodies (BsAbs) have revolutionized multiple myeloma (MM) treatment but are associated with infectious complications. This study aims to characterize the incidence, microbiological patterns, and risk factors for infection in this population. Methods: We conducted an observational cohort study of adult MM patients treated with BsAbs at a single center between 2020 and 2025. Clinical and microbiological features of different types of infection were analyzed. Risk factors for recurrent events were assessed by Cox regression. Results: Among 92 patients receiving 98 BsAb courses, 352 infectious episodes were identified (incidence rate: 3.20 episodes per BsAbs course-year). Most common syndromes were respiratory (71.3%) and digestive (11.9%), with predominant viral etiology (62.8%). Severe (grade ≥3) infections occurred in 45.9% of courses. Anti-BCMA BsAbs carried a higher infection risk than anti-GPRC5D therapy (aHR: 1.41, 95% CI: 1.02–1.94; P-value = 0.035). Previous BsAb exposure (aHR: 1.75, 95% CI: 1.23–2.50; P-value = 0.002), allogeneic hematopoietic stem-cell transplantation (aHR: 1.59, 95% CI: 1.12–2.26; P-value = 0.010), and development of immune effector cell-associated neurotoxicity syndrome (ICANS) (aHR: 3.23, 95% CI: 1.27–8.19; P-value = 0.001) increased the risk of infection. Intravenous immunoglobulin (IVIg) therapy was protective (aHR: 0.68, 95% CI: 0.53–0.86; P-value = 0.002). Concurrent infections were documented in only 6.8% of first episodes of cytokine release syndrome (CRS). Conclusions: BsAb therapy for MM is associated with a high infection burden, predominantly respiratory and gastrointestinal. Risk is driven by cumulative immunosuppression and therapy for ICANS, while IVIg therapy reduces this susceptibility. Infections are uncommon during CRS episodes.
- Open Access
Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice
Background: Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings. Objectives: We aimed to describe our real‐world experience with rezafungin for the treatment of invasive fungal disease (IFD). Patients: A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted. Results: We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent Candida species were C. albicans (38.5%), C. parapsilosis (30.8%) and Nakaseomyces glabratus (15.4%). One patient had necrotizing gingival infection due to Trichoderma longibrachiatum. Main types of IFD included intravascular Candida infection (38.5%) and surgical‐site and intra‐abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole‐resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug–drug interactions with triazoles (15.4%). No patient received rezafungin as a first‐line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow‐up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0–5.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12/12]), with no treatment‐emergent adverse events. Conclusions: Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep‐seated candidiasis.
Open AccessRezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice
Background: Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings. Objectives: We aimed to describe our real‐world experience with rezafungin for the treatment of invasive fungal disease (IFD). Patients: A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted. Results: We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent Candida species were C. albicans (38.5%), C. parapsilosis (30.8%) and Nakaseomyces glabratus (15.4%). One patient had necrotizing gingival infection due to Trichoderma longibrachiatum. Main types of IFD included intravascular Candida infection (38.5%) and surgical‐site and intra‐abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole‐resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug–drug interactions with triazoles (15.4%). No patient received rezafungin as a first‐line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow‐up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0–5.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12/12]), with no treatment‐emergent adverse events. Conclusions: Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep‐seated candidiasis.
- 2 December 2025
- Published by Elsevier in Journal of Hospital Infection
- Vol. 168, 88-96
Implementation of a novel aseptic insertion device for peripheral venous catheters: safety, performance, and nurse satisfaction
- 2 December 2025
- Published by Elsevier in Journal of Hospital Infection
- Vol. 168, 88-96
Implementation of a novel aseptic insertion device for peripheral venous catheters: safety, performance, and nurse satisfaction
- Open Access
- 12 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf691
Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review
Bruton tyrosine kinase inhibitors (BTKis) have been associated with an increased risk of invasive fungal disease, with skin and soft tissue mucormycosis accounting for a minority of cases. We present a 72-year-old patient with chronic lymphocytic leukemia who developed necrotizing fasciitis and myositis due to Lichtheimia spp after 4 months of therapy with the second-generation BTKi zanubrutinib, with a fatal outcome despite aggressive treatment. Our literature review identified 7 additional cases of BTKi-associated skin and soft tissue mucormycosis, revealing an all-cause mortality rate of 37.5%. Two-thirds of the patients had a previous trauma or skin lesion.
- 12 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf691
Open AccessSkin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review
Bruton tyrosine kinase inhibitors (BTKis) have been associated with an increased risk of invasive fungal disease, with skin and soft tissue mucormycosis accounting for a minority of cases. We present a 72-year-old patient with chronic lymphocytic leukemia who developed necrotizing fasciitis and myositis due to Lichtheimia spp after 4 months of therapy with the second-generation BTKi zanubrutinib, with a fatal outcome despite aggressive treatment. Our literature review identified 7 additional cases of BTKi-associated skin and soft tissue mucormycosis, revealing an all-cause mortality rate of 37.5%. Two-thirds of the patients had a previous trauma or skin lesion.
- Open Access
- 26 April 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70038
Knowledge and Adherence to Lifestyle Habits to Prevent Complications Associated With Immunosuppression in Kidney Transplant Recipients: A Single‐Center Survey
Background: Chronic immunosuppression associated with certain lifestyle habits render kidney transplant (KT) recipients more susceptible to infection and cancer. We assessed the level of knowledge and adherence to safe living strategies to minimize the occurrence of posttransplant complications. Methods: Consecutive KT recipients were offered a self‐administered questionnaire covering the following areas: demographics and socioeconomic factors; generic hygiene habits; sun exposure; smoking and alcohol consumption; vaccination status; animal contact and gardening; international travelling; and food safety and habits. Results: Between May 2019 and May 2021, 130 KT recipients responded the survey at a median of 61.5 posttransplant days (completion rate of 94.9%). Only 19.7% of participants visited the dentist at least every 3–6 months. Although the majority (88.5%) were aware of the need of sunscreen, only 23.3% used it throughout the year. Self‐reported influenza vaccine uptake in the last session was 69.1%. Pet ownership was reported by 41.7% of participants, of which more than one‐third had considered to give up the care of their animals. Gardening and international travel were uncommon. A notable proportion of participants acknowledged to consume the following products either “usually” or “often”: raw or undercooked meat (12.4%), undercooked fish (24.8%), raw seafood (8.8%), homemade sausages or cured ham (51.5%), pâté or meat spreads (35.2%), and “ready‐to‐eat” salads (31.8%). Adherence was poorer among non‐native‐speaking patients and those with lower education and household incomes. Conclusion: There is room for improvement in health education and promotion practices among KT recipients, particularly those with potential cultural and socioeconomic barriers.
- 26 April 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (4) , e70038
Open AccessKnowledge and Adherence to Lifestyle Habits to Prevent Complications Associated With Immunosuppression in Kidney Transplant Recipients: A Single‐Center Survey
Background: Chronic immunosuppression associated with certain lifestyle habits render kidney transplant (KT) recipients more susceptible to infection and cancer. We assessed the level of knowledge and adherence to safe living strategies to minimize the occurrence of posttransplant complications. Methods: Consecutive KT recipients were offered a self‐administered questionnaire covering the following areas: demographics and socioeconomic factors; generic hygiene habits; sun exposure; smoking and alcohol consumption; vaccination status; animal contact and gardening; international travelling; and food safety and habits. Results: Between May 2019 and May 2021, 130 KT recipients responded the survey at a median of 61.5 posttransplant days (completion rate of 94.9%). Only 19.7% of participants visited the dentist at least every 3–6 months. Although the majority (88.5%) were aware of the need of sunscreen, only 23.3% used it throughout the year. Self‐reported influenza vaccine uptake in the last session was 69.1%. Pet ownership was reported by 41.7% of participants, of which more than one‐third had considered to give up the care of their animals. Gardening and international travel were uncommon. A notable proportion of participants acknowledged to consume the following products either “usually” or “often”: raw or undercooked meat (12.4%), undercooked fish (24.8%), raw seafood (8.8%), homemade sausages or cured ham (51.5%), pâté or meat spreads (35.2%), and “ready‐to‐eat” salads (31.8%). Adherence was poorer among non‐native‐speaking patients and those with lower education and household incomes. Conclusion: There is room for improvement in health education and promotion practices among KT recipients, particularly those with potential cultural and socioeconomic barriers.
- Open Access
- 5 March 2025
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (3) , 222-227
Optimizing compliance with latent tuberculosis infection screening among kidney transplant recipients
Introduction: The increased risk of tuberculosis (TB) reactivation in solid organ transplant recipients supports the recommendation of screening for latent tuberculosis infection (LTBI). Adherence to available screening tests has not been studied in the kidney transplant (KT) population. We aimed to assess screening compliance within the ATALANTA-DOS population study. Methods: ATALANTA-DOS studied an intervention bundle aimed at preventing infection in KT recipients. We compared LTBI screening rates between the pre-intervention (February 2016 – September 2017) and intervention (February 2018 – September 2019) cohorts and evaluated adherence rates between the interferon-gamma release assay (IGRA) and the tuberculin skin test (TST). Results: A total of 307 KT recipients were included (155 in the pre-intervention cohort; 148 in the intervention cohort). A systematic assessment of screening compliance by an infectious disease specialist on day +30 post-KT improved LTBI screening adherence (82.6% [114/138] vs 1.3% [2/155]; p-value <0.001). In the intervention cohort, compliance was higher with IGRA (83.3% [52/62]) than with TST (68.1% [49/72]). Two cases of LTBI were detected in the pre-intervention cohort and five in the intervention cohort (4.4% [5/114]). All patients completed LTBI treatment after ruling out active TB. No cases of active TB were identified during follow-up. Conclusions: Systematic evaluation of LTBI screening compliance significantly increased screening completion rates among KT recipients. IGRA-based strategies increased screening compliance, supporting their implementation over TST for LTBI screening among KT recipients. Increased adherence would allow a more targeted and effective treatment of LTBI.
- 5 March 2025
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (3) , 222-227
Open AccessOptimizing compliance with latent tuberculosis infection screening among kidney transplant recipients
Introduction: The increased risk of tuberculosis (TB) reactivation in solid organ transplant recipients supports the recommendation of screening for latent tuberculosis infection (LTBI). Adherence to available screening tests has not been studied in the kidney transplant (KT) population. We aimed to assess screening compliance within the ATALANTA-DOS population study. Methods: ATALANTA-DOS studied an intervention bundle aimed at preventing infection in KT recipients. We compared LTBI screening rates between the pre-intervention (February 2016 – September 2017) and intervention (February 2018 – September 2019) cohorts and evaluated adherence rates between the interferon-gamma release assay (IGRA) and the tuberculin skin test (TST). Results: A total of 307 KT recipients were included (155 in the pre-intervention cohort; 148 in the intervention cohort). A systematic assessment of screening compliance by an infectious disease specialist on day +30 post-KT improved LTBI screening adherence (82.6% [114/138] vs 1.3% [2/155]; p-value <0.001). In the intervention cohort, compliance was higher with IGRA (83.3% [52/62]) than with TST (68.1% [49/72]). Two cases of LTBI were detected in the pre-intervention cohort and five in the intervention cohort (4.4% [5/114]). All patients completed LTBI treatment after ruling out active TB. No cases of active TB were identified during follow-up. Conclusions: Systematic evaluation of LTBI screening compliance significantly increased screening completion rates among KT recipients. IGRA-based strategies increased screening compliance, supporting their implementation over TST for LTBI screening among KT recipients. Increased adherence would allow a more targeted and effective treatment of LTBI.
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf025
Breakthrough Invasive Mold Infections in Hematologic Cases: Relevance of the Host's Factors
Background: Breakthrough invasive mold infections (bIMIs) are life-threatening complications in hematologic cases. Most previous studies in this field covered the whole spectrum of fungal pathogens, including yeasts, and antifungal agents. Methods: We conducted a retrospective study including all hematologic cases of patients diagnosed with a bIMI while receiving a mold-active antifungal agent at our center between January 2017 and June 2022. Results: Overall 37 patients were diagnosed with bIMI: 6 (16.2%) proven, 18 (48.6%) probable, and 13 (35.1%) possible. The highest incidence rate was found for micafungin (1.31 bIMI episodes per 1000 treatment-days), although with no significant differences across antifungal agents. Most patients (90.9%) for whom therapeutic drug monitoring was performed exhibited adequate through levels. Ten (27.0%) patients had undergone allogeneic hematopoietic stem cell transplantation. Aspergillus species was the most common pathogen in cases with microbiological identification. Regarding risk factors, 67.6% had severe neutropenia at diagnosis and 40.5% had received high-intensity chemotherapy. Rates of clinical response and attributable mortality by day +30 were 64.9% and 23.3%, respectively. Poorer performance status, higher Charlson Comorbidity index, older age, and higher C-reactive protein by day +7 were associated with 30-day attributable mortality. Conclusions: Aspergillus was the predominant pathogen in our cohort of bIMIs, with a significant proportion of episodes occurring despite adequate triazole levels. Thirty-day attributable mortality was lower than previously reported. Poorer performance status, higher comorbidity burden, and older age had a relevant role in the outcome of bIMI.
- 17 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf025
Open AccessBreakthrough Invasive Mold Infections in Hematologic Cases: Relevance of the Host's Factors
Background: Breakthrough invasive mold infections (bIMIs) are life-threatening complications in hematologic cases. Most previous studies in this field covered the whole spectrum of fungal pathogens, including yeasts, and antifungal agents. Methods: We conducted a retrospective study including all hematologic cases of patients diagnosed with a bIMI while receiving a mold-active antifungal agent at our center between January 2017 and June 2022. Results: Overall 37 patients were diagnosed with bIMI: 6 (16.2%) proven, 18 (48.6%) probable, and 13 (35.1%) possible. The highest incidence rate was found for micafungin (1.31 bIMI episodes per 1000 treatment-days), although with no significant differences across antifungal agents. Most patients (90.9%) for whom therapeutic drug monitoring was performed exhibited adequate through levels. Ten (27.0%) patients had undergone allogeneic hematopoietic stem cell transplantation. Aspergillus species was the most common pathogen in cases with microbiological identification. Regarding risk factors, 67.6% had severe neutropenia at diagnosis and 40.5% had received high-intensity chemotherapy. Rates of clinical response and attributable mortality by day +30 were 64.9% and 23.3%, respectively. Poorer performance status, higher Charlson Comorbidity index, older age, and higher C-reactive protein by day +7 were associated with 30-day attributable mortality. Conclusions: Aspergillus was the predominant pathogen in our cohort of bIMIs, with a significant proportion of episodes occurring despite adequate triazole levels. Thirty-day attributable mortality was lower than previously reported. Poorer performance status, higher comorbidity burden, and older age had a relevant role in the outcome of bIMI.